135 related articles for article (PubMed ID: 1371898)
1. Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide.
Joensuu H; Kätkä K; Kujari H
Acta Endocrinol (Copenh); 1992 Feb; 126(2):184-5. PubMed ID: 1371898
[TBL] [Abstract][Full Text] [Related]
2. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
3. Octreotide as a rapid and effective painkiller for metastatic carcinoid tumor.
Katai M; Sakurai A; Inaba H; Ikeo Y; Yamauchi K; Hashizume K
Endocr J; 2005 Apr; 52(2):277-80. PubMed ID: 15863961
[TBL] [Abstract][Full Text] [Related]
4. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours.
Tiensuu Janson EM; Ahlström H; Andersson T; Oberg KE
Eur J Cancer; 1992; 28A(10):1647-50. PubMed ID: 1382492
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
Deguchi H; Deguchi K; Tsukada T; Murashima S; Iwasaki E; Tsuda M; Kobayashi T; Shirakawa S
Intern Med; 1994 Feb; 33(2):100-2. PubMed ID: 7517229
[TBL] [Abstract][Full Text] [Related]
6. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?
Välimäki M; Järvinen H; Salmela P; Sane T; Sjöblom SM; Pelkonen R
Cancer; 1991 Feb; 67(3):547-9. PubMed ID: 1702352
[TBL] [Abstract][Full Text] [Related]
7. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
Kölby L; Persson G; Franzén S; Ahrén B
Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
[TBL] [Abstract][Full Text] [Related]
9. Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors.
Schell SR; Camp ER; Caridi JG; Hawkins IF
J Gastrointest Surg; 2002; 6(5):664-70. PubMed ID: 12399054
[TBL] [Abstract][Full Text] [Related]
10. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
Linkesch M; Kuzmits R; Geyer G
Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566
[TBL] [Abstract][Full Text] [Related]
11. Novel therapy for the treatment of human carcinoid.
Evers BM; Hurlbut SC; Tyring SK; Townsend CM; Uchida T; Thompson JC
Ann Surg; 1991 May; 213(5):411-6. PubMed ID: 1708983
[TBL] [Abstract][Full Text] [Related]
12. Carcinoid encephalopathy: A single entity or a spectrum of different disorders?
Lapeire LD; Tansens A; Lemmens GM; Van Belle SJ
Acta Oncol; 2010; 49(2):268-70. PubMed ID: 20001498
[No Abstract] [Full Text] [Related]
13. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
Biesma B; Willemse PH; Mulder NH; Verschueren RC; Kema IP; de Bruijn HW; Postmus PE; Sleijfer DT; de Vries EG
Br J Cancer; 1992 Nov; 66(5):850-5. PubMed ID: 1384643
[TBL] [Abstract][Full Text] [Related]
14. Recombinant alpha-2b interferon in patients with malignant carcinoid tumour.
Basser RL; Lieschke GJ; Sheridan WP; Fox RM; Green MD
Aust N Z J Med; 1991 Dec; 21(6):875-8. PubMed ID: 1726359
[TBL] [Abstract][Full Text] [Related]
15. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
Yao JC; Phan A; Hoff PM; Chen HX; Charnsangavej C; Yeung SC; Hess K; Ng C; Abbruzzese JL; Ajani JA
J Clin Oncol; 2008 Mar; 26(8):1316-23. PubMed ID: 18323556
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
[TBL] [Abstract][Full Text] [Related]
17. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide.
Creutzfeldt W; Bartsch HH; Jacubaschke U; Stöckmann F
Acta Oncol; 1991; 30(4):529-35. PubMed ID: 1713038
[TBL] [Abstract][Full Text] [Related]
18. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study.
Jacobsen MB; Hanssen LE; Kolmannskog F; Schrumpf E; Vatn MH; Bergan A
Scand J Gastroenterol; 1995 Aug; 30(8):789-96. PubMed ID: 7481548
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of metastatic carcinoid tumors with interferon-alpha. Five cases].
Votte A; Iglicki F; Sévenet F; Tabah I; Dupas JL
Presse Med; 1996 Jan; 25(2):63-7. PubMed ID: 8745720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
